News Agency
The Times

CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

  • Written by PR Newswire

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly.

CG-0416 is designed based on CureGene's proprietary prodrug platform,...

Read more: CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical...

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion